Zomedica Announces License & Supply Agreement with Cresilon Inc. to Market and Sell Vetigel(R) Hemostatic Gel in the Animal Health Market

Key Takeaways:

• Zomedica enters a license and supply agreement with Cresilon, Inc.
• Gains exclusive rights to sell Vetigel® in the United States.
• Vetigel® is a groundbreaking hemostatic gel technology.
• The agreement expands Zomedica’s veterinary product offerings.
• Non-exclusive distribution rights secured outside the U.S.

Zomedica Expands Portfolio with Exclusive Vetigel® Agreement

A Strategic Partnership in Veterinary Health

Zomedica Corp., a veterinary health company specializing in point-of-care diagnostics and therapeutic products for equine and companion animals, announced on January 7, 2025, that it has entered into a license and supply agreement with Cresilon, Inc. This pivotal agreement grants Zomedica exclusive rights to market and sell Cresilon’s revolutionary Vetigel® hemostatic gel product line in the United States, along with non-exclusive rights for markets outside the U.S.

Introducing a Revolutionary Hemostatic Technology

Vetigel® is a groundbreaking hemostatic gel designed to control bleeding efficiently in animals. The gel represents a significant advancement in veterinary care, providing veterinarians with a rapid and effective solution for managing bleeding during surgical procedures and emergency situations.

“Expanding Our Therapeutic Offerings”

“Zomedica today announced that it had entered into a license and supply agreement with Cresilon, Inc.,” the company stated, highlighting the strategic importance of this partnership. By adding Vetigel® to its portfolio, Zomedica reinforces its commitment to delivering innovative products that enhance animal health and support veterinary professionals.

Exclusive Rights in the United States

The agreement’s exclusivity in the U.S. positions Zomedica as the sole provider of Vetigel® to American veterinarians. This exclusivity is expected to strengthen Zomedica’s market presence and offer competitive advantages in the veterinary health sector.

Non-Exclusive Global Opportunities

Outside the United States, Zomedica secured non-exclusive rights to distribute Vetigel®. This aspect of the agreement opens opportunities for international expansion and allows Zomedica to meet the growing global demand for advanced veterinary technologies.

Enhancing Veterinary Care

The inclusion of Vetigel® in Zomedica’s product line is anticipated to have a positive impact on veterinary practices. The gel’s ability to promptly control bleeding can improve surgical outcomes and patient recovery times, ultimately elevating the standard of care provided to animals.

A Forward-Looking Collaboration

This license and supply agreement marks a significant milestone for both Zomedica and Cresilon, Inc. It not only broadens Zomedica’s therapeutic offerings but also advances the availability of innovative medical solutions in the animal health industry.

Conclusion

With this strategic partnership, Zomedica continues to solidify its role as a leader in veterinary health. The exclusive distribution of Vetigel® in the U.S. underscores the company’s dedication to introducing cutting-edge technologies that benefit both veterinarians and their patients.